Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIDE pilot phase II study in relapsed or refractory peripheral T-cell lymphomas
2024-513295-18-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor, ifosfamide, etoposide and dexamethasone sodium phosphate in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and 1 more, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall response rate. Planned start May 2024; status: authorised.
02
Drugs
selinexorifosfamideetoposidedexamethasone sodium phosphate
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)T follicular helper cell lymphoma (TFHL)
Beyond the preview
Go deeper on 2024-513295-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513295-18-00.